227 related articles for article (PubMed ID: 32401685)
1. Safety of Immune Checkpoint Inhibitors in Patients With Pre-Existing Inflammatory Bowel Disease and Microscopic Colitis.
Grover S; Ruan AB; Srivoleti P; Giobbie-Hurder A; Braschi-Amirfarzan M; Srivastava A; Buchbinder EI; Ott PA; Kehl KL; Awad MM; Hodi FS; Rahma OE
JCO Oncol Pract; 2020 Sep; 16(9):e933-e942. PubMed ID: 32401685
[TBL] [Abstract][Full Text] [Related]
2. Characteristics and outcomes of cancer patients with pre-existing microscopic colitis after exposure to PD-1 and PD-L1 inhibitors.
Thomas AR; Liu C; Tong YT; Tan D; Altan M; Siddiqui BA; Shatila M; Khan A; Thomas AS; Wang Y
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5429-5436. PubMed ID: 36451045
[TBL] [Abstract][Full Text] [Related]
3. Incidence of immune checkpoint inhibitor-mediated diarrhea and colitis (imDC) in patients with cancer and preexisting inflammatory bowel disease: a propensity score-matched retrospective study.
Sleiman J; Wei W; Shah R; Faisal MS; Philpott J; Funchain P
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34158318
[TBL] [Abstract][Full Text] [Related]
4. Systematic review with meta-analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel diseases.
Meserve J; Facciorusso A; Holmer AK; Annese V; Sandborn WJ; Singh S
Aliment Pharmacol Ther; 2021 Feb; 53(3):374-382. PubMed ID: 33314269
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of Immune Checkpoint Inhibitor-Induced Colitis: A Systematic Review.
Nakane T; Mitsuyama K; Yamauchi R; Kakuma T; Torimura T
Kurume Med J; 2023 Jul; 68(2):43-52. PubMed ID: 37100606
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course.
Haryal A; Townsend MJ; Baskaran V; Srivoleti P; Giobbie-Hurder A; Sack JS; Isidro RA; LeBoeuf NR; Buchbinder EI; Hodi FS; Grover S
Cancer; 2023 Feb; 129(3):367-375. PubMed ID: 36377339
[TBL] [Abstract][Full Text] [Related]
7. Management of immune checkpoint inhibitor in patients with cancer and pre-existing inflammatory bowel disease: Recommendations from the GETAID.
Amiot A; Laharie D; Malamut G; Serrero M; Poullenot F;
Dig Liver Dis; 2022 Sep; 54(9):1162-1167. PubMed ID: 35842365
[TBL] [Abstract][Full Text] [Related]
8. Use of Immune Checkpoint Inhibitors in Patients With Pre-established Inflammatory Bowel Diseases: Retrospective Case Series.
Braga Neto MB; Ramos GP; Loftus EV; Faubion WA; Raffals LE
Clin Gastroenterol Hepatol; 2021 Jun; 19(6):1285-1287.e1. PubMed ID: 32565289
[TBL] [Abstract][Full Text] [Related]
9. Disease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy.
Rubin SJS; Balabanis T; Gubatan J; Habtezion A
World J Clin Cases; 2022 Feb; 10(6):1787-1794. PubMed ID: 35317167
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy.
Halle BR; Betof Warner A; Zaman FY; Haydon A; Bhave P; Dewan AK; Ye F; Irlmeier R; Mehta P; Kurtansky NR; Lacouture ME; Hassel JC; Choi JS; Sosman JA; Chandra S; Otto TS; Sullivan R; Mooradian MJ; Chen ST; Dimitriou F; Long G; Carlino M; Menzies A; Johnson DB; Rotemberg VM
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34635495
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease.
Abu-Sbeih H; Faleck DM; Ricciuti B; Mendelsohn RB; Naqash AR; Cohen JV; Sellers MC; Balaji A; Ben-Betzalel G; Hajir I; Zhang J; Awad MM; Leonardi GC; Johnson DB; Pinato DJ; Owen DH; Weiss SA; Lamberti G; Lythgoe MP; Manuzzi L; Arnold C; Qiao W; Naidoo J; Markel G; Powell N; Yeung SJ; Sharon E; Dougan M; Wang Y
J Clin Oncol; 2020 Feb; 38(6):576-583. PubMed ID: 31800340
[TBL] [Abstract][Full Text] [Related]
12. Checkpoint Inhibitor-Induced Colitis: From Pathogenesis to Management.
Terrin M; Migliorisi G; Dal Buono A; Gabbiadini R; Mastrorocco E; Quadarella A; Repici A; Santoro A; Armuzzi A
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511260
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of appendectomy as a potential risk factor for immune checkpoint inhibitor-associated enterocolitis.
Krasnow NA; Chute DF; Falade AS; North CM; Reynolds KL; Dougan ML
Immunotherapy; 2023 Aug; 15(12):913-920. PubMed ID: 37292001
[TBL] [Abstract][Full Text] [Related]
14. Chronic Use of Proton Pump Inhibitors Is Associated With an Increased Risk of Immune Checkpoint Inhibitor Colitis in Renal Cell Carcinoma.
Yin J; Elias R; Peng L; Levonyak N; Asokan A; Christie A; Kubiliun N; Brugarolas J; Hammers HJ
Clin Genitourin Cancer; 2022 Jun; 20(3):260-269. PubMed ID: 35277350
[TBL] [Abstract][Full Text] [Related]
15. Dietary Considerations for Inflammatory Bowel Disease Are Useful for Treatment of Checkpoint Inhibitor-Induced Colitis.
Saha A; Dreyfuss I; Sarfraz H; Friedman M; Markowitz J
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612082
[TBL] [Abstract][Full Text] [Related]
16. Safety of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune disease.
Alexander S; Swami U; Kaur A; Gao Y; Fatima M; Ginn MM; Stein JE; Grivas P; Zakharia Y; Singh N
Ann Transl Med; 2021 Jun; 9(12):1033. PubMed ID: 34277833
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibitor Enterocolitis vs Idiopathic Inflammatory Bowel Disease.
Shirwaikar Thomas A; Hanauer S; Wang Y
Clin Gastroenterol Hepatol; 2023 Apr; 21(4):878-890. PubMed ID: 36270617
[TBL] [Abstract][Full Text] [Related]
18. Checkpoint Inhibitor Colitis Shows Drug-Specific Differences in Immune Cell Reaction That Overlap With Inflammatory Bowel Disease and Predict Response to Colitis Therapy.
Lo YC; Price C; Blenman K; Patil P; Zhang X; Robert ME
Am J Clin Pathol; 2021 Jul; 156(2):214-228. PubMed ID: 33555016
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitor-induced colitis: A comprehensive review.
Som A; Mandaliya R; Alsaadi D; Farshidpour M; Charabaty A; Malhotra N; Mattar MC
World J Clin Cases; 2019 Feb; 7(4):405-418. PubMed ID: 30842952
[TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Inhibitor-associated Diarrhea and Colitis: A Systematic Review and Meta-analysis of Observational Studies.
Tran AN; Wang M; Hundt M; Chugh R; Ohm J; Grimshaw A; Ciarleglio M; Hung KW; Proctor DD; Price CC; Laine L; Al-Bawardy B
J Immunother; 2021 Oct; 44(8):325-334. PubMed ID: 34380976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
